| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Departments of Pediatrics [H. S. F., J. K., S. X. S.], Pathology [H. S. F., D. D. B.], and Medicine [G. B. E., S. C. S.], Duke University Medical Center, Durham, North Carolina 27710; The Johns Hopkins Oncology Center, Baltimore, Maryland 21205 [O. M. C., J. H.]; and Burroughs Wellcome Co., Research Triangle Park, North Carolina 27709 [M. R. B., P. M. S.]
Melphalan transport, glutathione levels, and glutathione-S-transferase activity were measured in two continuous human medulloblastoma cell lines and transplantable xenografts in athymic nude mice, TE-671 and Daoy. In vitro mean glutathione levels were 10.06 nmol/106 cells in TE-671 and 2.96 nmol/106 cells in Daoy. In vitro mean glutathione-S-transferase values were 91.52 nmol/min/mg protein in TE-671 and 50.31 nmol/min/mg protein in Daoy. Transport studies revealed kinetic parameters of Km = 108.3 µM, Vmax = 363.1 pmol/106 cells/min in TE-671 and Km = 111.7 µM, Vmax = 180.6 pmol/106 cells/min in Daoy. Melphalan transport was inhibited by both DL-
-2-aminobicyclo[2.2.1]heptane-2-carboxylic acid and sodium ion depletion in TE-671 and Daoy cells in vitro, indicating that both systems of amino acid transport are functional in these medulloblastoma lines. In vivo s.c. xenograft glutathione values were lower (7.79 nmol/mg protein) in TE-671 than in Daoy (13.68 nmol/mg protein). The mean plasma concentration in mice given a 10% lethal dose (71.3 mg/m2) of melphalan i.p. was 50.3 µM at 10 min, with the half-life of 29.9 min. At this dose, s.c. xenograft levels were 2- to 3-fold higher in TE-671 than in Daoy tumors for the 3-h period measured. These studies demonstrate transport parameters confirming facilitated transport of melphalan in human medulloblastoma, a mean murine plasma melphalan concentration (following treatment with melphalan) above the in vitro drug dose at which there is a 90% reduction in the number of colonies in comparison to controls for TE-671 and Daoy for 2 h, and glutathione and glutathione-S-transferase levels in the same range previously reported in other melphalan-sensitive and melphalan-resistant human tumors. Future work with spontaneous and acquired melphalan-resistant human medulloblastoma cell lines and xenografts will define the role of these mechanisms in mediating drug resistance.
1 This work was supported by NIH Grants CA11898, 1 NINCDS NS 20023, 1 K07 NS 00958, and CA44640, and by American Chemical Society Grant 403.
2 To whom requests for reprints should be addressed at Department of Pediatrics, Duke University Medical Center, Durham, NC 27710.
Received 3/17/88. Revised 6/17/88. Accepted 6/28/88.
This article has been cited by other articles:
![]() |
M. D. Bacolod, S. P. Johnson, F. Ali-Osman, P. Modrich, N. S. Bullock, O. M. Colvin, D. D. Bigner, and H. S. Friedman Mechanisms of Resistance to 1,3-Bis(2-chloroethyl)-1-nitrosourea in Human Medulloblastoma and Rhabdomyosarcoma Mol. Cancer Ther., July 1, 2002; 1(9): 727 - 736. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |